PET predicts chemotherapy responses in breast cancer patients
PET/CT with gallium-68 (Ga-68) FAPI radiotracer can predict responses to neoadjuvant chemotherapy in breast cancer patients, according to a study published November 2 in the Journal of Nuclear Medicine. A team in Fuzhou, China, found that Ga-68 FAPI uptake on early PET/CT scans during chemotherapy indicated which patients were most likely to experience complete responses. This information can have a major impact on how patients are guided through treatment, according to the authors.“Ga-68 FAPI-PET/CT parameters can rapidly provide feedback on tumor changes after only two cycles of chemotherapy,” wrote first author Ling...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Will Morton Tags: Clinical News Subspecialties Molecular Imaging Nuclear Medicine Breast Imaging Source Type: news

Omitting Surgery May Be Safe in Early BC After pCR Omitting Surgery May Be Safe in Early BC After pCR
A small trial has helped to further identify women who can safely skip surgery after neoadjuvant therapy for early breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

CT radiomics help characterize retroperitoneal sarcomas
CT radiomics can help clinicians predict the histological type and grade of retroperitoneal sarcomas, a study published in the November issue of The Lancet Oncology has found.The results could have "important implications for improving diagnosis and risk stratification" of these cancers, wrote a team led by Amani Arthur, MD, of the Institute of Cancer Research in London, U.K."Our radiomics model to predict histological subtype and grade presents a conceptual advance and an opportunity for a change in personalized care for patients with retroperitoneal sarcoma," the group noted.Retroperitoneal sarcomas are large and comp...
Source: AuntMinnie.com Headlines - November 2, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Imaging Informatics Advanced Visualization Source Type: news

3D imaging modeling cost effective for pediatric surgery
3D anatomical modeling using advanced imaging software can be cost-effective in planning pediatric surgeries, according to research published October 28 in the Journal of Pediatric Surgery. A team led by Mark Ryan, MD, from the University of Texas Southwestern Medical Center in Dallas found that its modeling approach can successfully visualize pediatric anatomical structures. From there, these 3D structures can be retained for 3D printing, virtual reality usage, or as an anatomic reference. “Visualization and preoperative planning can be assisted by advanced imaging software at minimal to no cost, thereby facilitating...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Advanced Visualization Source Type: news

3D imaging modeling cost-effective for pediatric surgery
3D anatomical modeling using advanced imaging software can be cost-effective in planning pediatric surgeries, according to research published October 28 in the Journal of Pediatric Surgery. A team led by Mark Ryan, MD, from the University of Texas Southwestern Medical Center in Dallas found that its modeling approach can successfully visualize pediatric anatomical structures. From there, these 3D structures can be retained for 3D printing, virtual reality usage, or as an anatomic reference. “Visualization and preoperative planning can be assisted by advanced imaging software at minimal to no cost, thereby facilitating...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 3D Printing Source Type: news

Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On
The question of whether to give upfront immunochemotherapy in resectable non –small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC
(MedPage Today) -- MADRID -- Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival rates in patients with resectable stage II-IV cutaneous squamous cell carcinoma (SCC), according to follow-up results from a small... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 26, 2023 Category: Dermatology Source Type: news

ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer ICIs Improve pCR Rates in Early ER+/HER2 – Breast Cancer
Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor –positive, HER2-negative breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Perioperative Nivolumab Improves EFS in Resectable NSCLC Perioperative Nivolumab Improves EFS in Resectable NSCLC
Interim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can Some Patients With Esophageal Cancer Avoid Surgery? Can Some Patients With Esophageal Cancer Avoid Surgery?
About one third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery. However, one expert questioned the study design.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer Neoadjuvant Advantages: Treating Locally Advanced Lung Cancer
Mark G. Kris, MD, discusses neoadjuvant therapy for patients with locally advanced lung cancers.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2023 Category: Drugs & Pharmacology Source Type: news

Bladder-Sparing Neoadjuvant Protocol Gets High Marks for MIBC
(MedPage Today) -- More than 40% of patients with muscle-invasive bladder cancer (MIBC) avoided immediate cystectomy after achieving a clinical complete response (cCR) with a chemoimmunotherapy combination, a prospective study showed. Overall... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 6, 2023 Category: Hematology Source Type: news